Figure 7.

Triptolide treatment alleviated DSS-induced intestinal inflammation through the PDE4B/AKT/NF-κB axis in vivo and in vitro. Mice aged 6–8 weeks were treated with 2.5% DSS with or without triptolide administration. (A) Western blots were used to measure the protein levels of PDE4B, total AKT, phosphorylated AKT, total P65, and phosphorylated P65 in colitis tissue. RAW 264.7 macrophages were treated with 1000 ng/ml LPS plus 0–40 nM triptolide for 24 h. (B) Western blots were used to measure the protein levels of PDE4B, total AKT, phosphorylated AKT, total P65, and phosphorylated P65 in RAW 264.7 macrophages. (C) Immunofluorescence assays were performed to determine PDE4B and phosphorylated P65 levels. (D) The flowchart of triptolide in the DSS-induced colitis model. Data are shown as the mean ± SD of at least three independent experiments.